within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XE03_Furazidin;

model Furazidin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.2,
    Cl = 2.3333333333333332e-05,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0016666666666666668,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Furazidin</td></tr><tr><td>ATC code:</td><td>J01XE03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.2</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Furazidin is a nitrofuran class antibacterial drug mainly used for the treatment of uncomplicated urinary tract infections. It is approved and used in some Eastern European countries, but not widely approved or available in Western Europe or the United States.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a healthy adult population based on available limited data for nitrofuran derivatives and related compounds. No direct published pharmacokinetic studies with detailed compartmental modeling for furazidin were found.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01XE03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Furazidin;
